Results 151 to 160 of about 774,787 (241)

An Integrated Text Mining Approach for Discovering Pharmacological Effects, Drug Combinations, and Repurposing Opportunities of ACE Inhibitors. [PDF]

Int J Mol Sci
Biziukova NY, Savosina PI, Druzhilovskiy DS, Tarasova OA, Poroikov VV.   +4 more
europepmc   +1 more source

Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine. [PDF]

Sci Rep, 2023
Schneider BK, Ward J, Sotillo S, Garelli-Paar C, Guillot E, Prikazsky M, Mochel JP.   +6 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers. [PDF]

Front Pharmacol
Zhuang M, Chen M.
europepmc   +1 more source

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19. [PDF]

Ir J Med Sci, 2023
Najafi N, Davoudi A, Izadyar H, Alishahi A, Mokhtariani A, Soleimanpourian B, Tabarrayi M, Moosazadeh M, Daftarian Z, Ahangarkani F.   +9 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Isoindolines and Isoindoline-1,3-diones as Nonpeptide ACE Inhibitors: An <i>In Silico</i> and <i>In Vitro</i> Modeling Approach. [PDF]

ACS Med Chem Lett
Rodríguez JE, Lagos-Cruz JA, Villalobos-Molina R, Cuevas-Hernández RI, Gallardo-Ortíz IA, Andrade-Jorge E.   +5 more
europepmc   +1 more source

Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension. [PDF]

J Renin Angiotensin Aldosterone Syst, 2023
Ahmad H, Khan H, Haque S, Ahmad S, Srivastava N, Khan A.   +5 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source